Kobayashi Tomoo, Inoue Jun, Tanaka Yu, Yamakawa Mitsuru, Kurihara Makoto, Handa Tomoko, Kondo Yutaka, Saitou Akihiro, Shiraki Manabu, Kojima Yasuhiro, Ohyauchi Motoki, Masamune Atsushi
Department of Gastroenterology Tohoku Rosai Hospital Sendai Japan.
Division of Gastroenterology Tohoku University Graduate School of Medicine Sendai Japan.
JGH Open. 2025 Mar 18;9(3):e70124. doi: 10.1002/jgh3.70124. eCollection 2025 Mar.
Serum zinc levels decrease in chronic liver disease (CLD), but their effects on liver reserve function, tyrosine, skeletal muscle mass, handgrip strength (HGS), and hepatocellular carcinoma (HCC) development remain poorly understood.
A retrospective, cross-sectional study was conducted on 516 CLD cases. Patients were divided into a low zinc group (< 80 μg/dL) and a high zinc group (≥ 80 μg/dL). Serum zinc levels were analyzed with liver reserve function (assessed by modified albumin-bilirubin [mALBI] grade), tyrosine, branched-chain amino acid/tyrosine ratio (BTR), and HCC development. In 180 cases, the relationship between serum zinc levels and skeletal muscle characteristics, including sarcopenia and HGS, was investigated.
Tyrosine levels increased significantly with mALBI grade progression. Patients in the low zinc group had higher tyrosine levels (76.9 vs. 67.2 μmol/L, < 0.001), a greater proportion of high tyrosine levels (5.3% vs. 1.7%, < 0.001), and more HCC cases (10.5% vs. 3.7%, < 0.005). Zinc levels were lower with more severe CLD (81 μg/dL [mALBI grade 1] vs. 35.2 μg/dL [grade 3], < 0.001). Tyrosine levels were higher in HCC patients than in non-HCC patients (93.1 vs. 70.7 μmol/L, < 0.001). Sarcopenia prevalence did not differ between groups (56.6% vs. 52.0%, = 0.344), but low HGS was more frequent in low zinc patients (61.2% vs. 46.3%, = 0.032). In a subset of patients with low zinc levels ( = 12), zinc supplementation reduced tyrosine levels after 3 months (86.3 vs. 73.3 μmol/L, = 0.017).
Hypozincemia is linked to elevated tyrosine levels, reduced HGS, increased HCC incidence, and CLD progression.
慢性肝病(CLD)患者血清锌水平降低,但其对肝脏储备功能、酪氨酸、骨骼肌质量、握力(HGS)和肝细胞癌(HCC)发生发展的影响仍知之甚少。
对516例CLD患者进行回顾性横断面研究。患者分为低锌组(<80μg/dL)和高锌组(≥80μg/dL)。分析血清锌水平与肝脏储备功能(通过改良白蛋白-胆红素[mALBI]分级评估)、酪氨酸、支链氨基酸/酪氨酸比值(BTR)和HCC发生发展的关系。在180例患者中,研究血清锌水平与骨骼肌特征(包括肌肉减少症和HGS)之间的关系。
酪氨酸水平随mALBI分级进展显著升高。低锌组患者酪氨酸水平较高(76.9对67.2μmol/L,<0.001),高酪氨酸水平的比例更高(5.3%对1.7%,<0.001),HCC病例更多(10.5%对3.7%,<0.005)。CLD越严重,锌水平越低(81μg/dL[mALBI 1级]对35.2μg/dL[3级],<0.001)。HCC患者的酪氨酸水平高于非HCC患者(93.1对70.7μmol/L,<0.001)。两组间肌肉减少症患病率无差异(56.6%对52.0%,=0.344),但低锌患者低HGS更常见(61.2%对46.3%,=0.032)。在一部分低锌水平患者(=12)中,补锌3个月后酪氨酸水平降低(86.3对73.3μmol/L,=0.017)。
低锌血症与酪氨酸水平升高、HGS降低、HCC发病率增加和CLD进展有关。